
Hepatocellular Carcinoma - Pipeline Insight, 2024
Description
Hepatocellular Carcinoma - Pipeline Insight, 2024
DelveInsight’s, “Hepatocellular Carcinoma - Pipeline Insight, 2024” report provides comprehensive insights about 90+ companies and 95+ pipeline drugs in Hepatocellular Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Hepatocellular Carcinoma: Overview
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Hepatocellular carcinoma occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection. Cirrhosis is a significant step in viral carcinogenesis for hepatocellular carcinoma. Integration of the hepatitis B virus genome into the host genome is the primary pathogenesis for oncogenesis in HBV. Insertion of viral genome in telomerase reverse transcriptase (TERT) promoter sites of the human genome resulting in mutation accounting for 60% of HCC cases. Other genetic alterations include mutations in TP53 (affecting cell cycle), beta-1 catenin (CTNNBI), axis inhibitor-1 (AXINI), AT-rich interaction domain-containing protein 1A (ARID1A), and ARID2(chromatin proliferation).
Chronic inflammation in chronic hepatitis C virus infection with subsequent fibrosis, necrosis, and regeneration contributes to HCC development. Molecular markers noted in liver carcinogenesis include viral structural and non-structural proteins (NS3, NS4A, NS4B, NS5A, and NS5B). HCV-associated HCC mostly occurs in patients with cirrhosis or advanced stages of fibrosis.
Modalities available for HCC screening include both radiographic tests and serological markers. Radiological tests commonly used for surveillance include ultrasonography (US), multiphase computerized tomography (CT), and magnetic resonance imaging (MRI) with contrast. To obtain the best treatment result for HCC, early diagnosis is the key. Chronic hepatitis leads to the development of cirrhosis. Cirrhotic livers exhibit regenerative nodules, which result from increased proliferation of hepatocytes. Differentiation between these regenerative nodules and HCC can vary based on the size of the nodules. Nodules <1 cm detected via US that cannot be defined should be followed up with a repeat US in 3–4 months. Nodules >1 cm detected via US should have further radiologic investigation including either contrast-enhanced triple or quadriphasic CT or MRI. The diagnosis of HCC is based on the contrast enhancement in the arterial phase (wash-in) followed by disappearance of the contrast in the venous phase (washout). A meta-analysis of the diagnostic performance of CT and MRI for evaluating HCC has demonstrated that MRI has a higher per-lesion sensitivity than multi detector CT and should be the preferred imaging modality for the diagnosis of HCC in patients with chronic liver disease. If the first radiologic test is equivocal, then confirmation with a different technique is recommended. If the diagnosis still remains uncertain, a serum AFP level >400 ng/mL has a high positive predictive value. Percutaneous biopsy should be limited to those nodules that are radio logically nontypical on CT or MRI for HCC.
Treatment modalities for HCC have evolved and given the variety of treatment options, a multi-disciplinary approach requiring input from surgical, medical, and radiation oncology, hepatology, and interventional radiology is necessary. Multiple advances have been made over the last decade regarding treatment of HCC, especially advanced disease. Resection and transplantation remain as cornerstone curative-intent treatment options. For patients who are not candidates for curative-intent therapy, exciting progress has been made in molecular and cellular approaches to systemic therapy for HCC including immunotherapies and tyrosine kinase inhibitors. Although the prognosis for advanced HCC remains poor, the armamentarium of therapies has increased, and valuable years of life can be gained with these therapies. While the main therapeutic modality for early-stage disease remains resection, multimodal immunotherapy has emerged as first-line treatment for advanced disease.
""Hepatocellular Carcinoma- Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Hepatocellular Carcinoma pipeline landscape is provided which includes the disease overview and Hepatocellular Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Hepatocellular Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Hepatocellular Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Hepatocellular Carcinoma.
This segment of the Hepatocellular Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Hepatocellular Carcinoma Emerging Drugs
- Namodenoson: Can-Fite BioPharma
- SRF388: Surface Oncology
- Porustobart: Harbour BioMed
As the first heavy chain only fully human antibody on clinical stage in the world, porustobart showed its good safety profile and strong efficacy on its monotherapy study of phase I trial. HBM is making all efforts to push forward to the studies of this product as treatment for multiple solid tumors, including melanoma, NSCLC, HCC, NET/NEC. . Currently, the drug is in the Phase II stage of its development for the treatment of Hepatocellular carcinoma.
- Fisogatinib: CStone Pharmaceuticals
- STP705: Sirnaomics
Additional immunohistochemistry and image analyses of the liver and tumor tissues demonstrated that animals treated with STP705 resulted in increased CD4+ and CD8+ T cell infiltration within the tumor microenvironment. Using STP705 for treatments of hepatocellular carcinoma and cholangiocarcinoma have been designated as Orphan Drug indications by the US FDA. Currently, the drug is in the Phase I stage of its development for the treatment of Hepatocellular carcinoma.
Further product details are provided in the report……..
Hepatocellular Carcinoma: Therapeutic Assessment
This segment of the report provides insights about the different Hepatocellular Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Hepatocellular Carcinoma
- There are approx. 90+ key companies which are developing the therapies for Hepatocellular Carcinoma. The companies which have their Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase III include, Can-Fite BioPharma.
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Hepatocellular Carcinoma: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Hepatocellular Carcinoma therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Hepatocellular Carcinoma drugs.
Hepatocellular Carcinoma Report Insights
- Hepatocellular Carcinoma Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Hepatocellular Carcinoma drugs?
- How many Hepatocellular Carcinoma drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Hepatocellular Carcinoma?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Hepatocellular Carcinoma therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Hepatocellular Carcinoma and their status?
- What are the key designations that have been granted to the emerging drugs?
- Can-Fite BioPharma
- Sinocelltech
- AVEO Oncology
- Oxford BioTherapeutics
- Beijing SyngenTech
- Surface Oncology
- Novartis Oncology
- Array BioPharma
- Taizhou Hanzhong Pharmaceuticals
- Akeso Biopharma
- Shanghai Henlius Biotech
- Chugai Pharmaceutical
- CStone Pharmaceuticals
- Shenogen Pharma
- GlaxoSmithKline
- Tarus Therapeutics
- Tvardi Therapeutics
- Virogin Biotech
- Yiviva
- Chia Tai Tianqing Pharmaceutical Group
- Antengene Corporation
- Iterion Therapeutics
- Sumitomo Pharma
- SillaJen Biotherapeutics
- SCG Cell Therapy
- Guangdong ProCapZoom Biosciences
- Eutilex
- Polaris Pharmaceuticals
- OriCell Therapeutics
- Namodenoson
- Tivozanib
- SCT-I10A
- OBT-624
- SynOV1.1
- SRF388
- INC280
- HX008
- AK104
- Serplulimab
- ERY974
- Fisogatinib
- Icaritin
- TSR-022
- TT-4
- TTI-101
- VG161
- YIV-906
- TQB2450
- ATG 008
- BBI608
- Tegavivint
- Pexastimogene Devacirepvec
- SCG101
- SZ003
- EU307
- ADI-PEG20
- Ori-C101
Table of Contents
230 Pages
- Introduction
- Executive Summary
- Hepatocellular Carcinoma: Overview
- Introduction
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Namodenoson: Can-Fite BioPharma
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- SRF388: Surface Oncology
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- STP705: Sirnaomics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Hepatocellular Carcinoma Key Companies
- Hepatocellular Carcinoma Key Products
- Hepatocellular Carcinoma- Unmet Needs
- Hepatocellular Carcinoma- Market Drivers and Barriers
- Hepatocellular Carcinoma- Future Perspectives and Conclusion
- Hepatocellular Carcinoma Analyst Views
- Hepatocellular Carcinoma Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.